TABLE 1.
Cardiopulmonary Hemodynamics*
| Sham | Saline | AAV1.SERCA2a | p Value (ANOVA) | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n = 4) | Final (n = 4) | Baseline (n = 10) | Final (n = 8) | Baseline (n = 10) | Final (n = 8) | Baseline (Between Groups) | Group/Time Interaction | |
| Body weight, kg | 21.5 (21–22.8) | 34 (31.5–36.3) | 20.5 (19–23) | 30.5 (28.5–32.5) | 22.5 (20.5–24.8) | 36 (34–37.3) | 0.547 | 0.237 |
| Heart rate, beats/min | 61 (55–66) | 75 (74–76) | 73 (71–84) | 73 (64–99) | 68 (57–82) | 78 (71–86) | 0.071 | 0.684 |
| Mean aortic pressure, mm Hg | 92 (89–99) | 121 (116–125) | 85 (80–93) | 103 (90–127) | 84 (81–90) | 112 (104–127) | 0.242 | 0.695 |
| Systolic PA pressure, mm Hg | 22 (21–22) | 23 (22–24) | 34 (30–44) | 70 (59–87) | 34 (28–38) | 40 (33–44) | <0.001† | 0.003†§ |
| Diastolic PA pressure, mm Hg | 10 (9–10) | 10 (9–10) | 15 (12–20) | 35 (29–46) | 14 (11–17) | 18 (15–20) | 0.014 | 0.004†§ |
| Mean PA pressure, mm Hg | 17 (15–18) | 16 (15–17) | 26 (23–30) | 54 (43–63) | 23 (19–28) | 29 (26–31) | 0.004†‡ | 0.003†§ |
| PA wedge pressure, mm Hg | 10 (8–10) | 9 (7–9) | 12 (10–14) | 15 (11–18) | 9 (5–11) | 12 (10–14) | 0.244 | 0.482 |
| Diastolic pulmonary gradient, mm Hg | 0 (0–2) | 0 (0–2) | 5 ([–1]–8) | 22 (10–26) | 4 (2–6) | 6 (1–9) | 0.281 | 0.01†§ |
| RA pressure, mm Hg | 4 (3–5) | 2 (1–2) | 2 (2–3) | 4 (3–5) | 4 (3–5) | 2 (1–3) | 0.044§ | 0.001†§ |
| Cardiac index, l/min/m2 | 3.38 (3.29–3.51) | 4.52 (4.3–4.86) | 4.33 (4.13–5.13) | 3.70 (3.14–4.68) | 4.06 (3.53–5.04) | 5.43 (4.71–5.76) | 0.004† | 0.052 |
| Stroke volume index, ml/m2 | 58 (54–61) | 60 (57–65) | 57 (51–70) | 51 (43–74) | 59 (50–71) | 65 (59–78) | 0.870 | 0.269 |
| PVR index, WU/m2 | 1.93 (1.29–3.03) | 1.56 (1.49–1.85) | 2.83 (2.55–4.38) | 10.3 (5.14–12.21) | 3.17 (2.3–4.8) | 3.17 (1.8–4) | 0.459 | 0.002†§ |
| SVR index, WU/m2 | 26 (24.6–28.7) | 27 (25.3–27.1) | 17.5 (17–22.4) | 27.4 (21.2–31.7) | 19.4 (18–22) | 21.9 (20.5–24.5) | 0.052 | 0.055 |
Values are median (interquartile range [IQR]).
*
Baseline was at 2 months after model creation and final was at 4 months after model creation (and 2 months after gene transfer).
†
Pairwise post hoc p < 0.05 sham versus saline.
‡
Pairwise post hoc p < 0.05 for sham versus AAV1.SERCA2a.
§
Pairwise post hoc p < 0.05 for saline versus AAV1.SERCA2a.
AAV1.SERCA2a = recombinant adeno-associated virus serotype 1 carrying the human SERCA2a transgene; ANOVA = analysis of variance; PA = pulmonary artery; PVR = pulmonary vascular resistance; RA = right atrium; SVR = systemic vascular resistance; WU = Wood units.